A Phase 1 Two-Arm, Randomized, Double-Blind, Active-Controlled Study of Live, Oral Plasmid-Derived Adenovirus Type 4 and Type 7 Vaccines in Seronegative Adults

Overview

Journal Vaccines (Basel)

Date 2023 Jun 28

PMID 37376480

Authors

Shannon Beaty

Natalie Collins

Nicos Karasavvas

Robert Kuschner

Jun Hang

Anima Adhikari

Irina Maljkovic Berry

Christian Fung

Shannon Walls

Elena Betancourt

Jason Mendy

Michael Lock

Emma Gierman

Sean Bennett

Paul Shabram

Kelly Warfield

Affiliations

Soon will be listed here.

Abstract

PXVX0047 is an investigational vaccine developed for active immunization to prevent febrile acute respiratory disease (ARD) caused by adenovirus serotypes 4 (Ad4) and 7 (Ad7). PXVX0047 consists of a modernized, plasmid-derived vaccine that was generated using a virus isolated from Wyeth Ad4 and Ad7 vaccine tablets. A phase 1 two-arm, randomized, double-blind, active-controlled study was conducted to evaluate the safety profile and immunogenicity of the investigational adenovirus vaccines. The two components of PXVX0047 were administered orally together in a single dose to 11 subjects. For comparison, three additional subjects received the Ad4/Ad7 vaccine that is currently in use by the US military. The results of this study show that the tolerability and immunogenicity of the PXVX0047 Ad7 component are comparable with that of the control Ad4/Ad7 vaccine; however, the immunogenicity of the PXVX0047 Ad4 component was lower than expected. Clinical trial number NCT03160339.

Citing Articles

The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies.

Wallace R, Bliss C, Parker A Viruses. 2024; 16(6).

PMID: 38932265 PMC: 11209478. DOI: 10.3390/v16060973.

References

Chanock R, Ludwig W, Heubner R, CATE T, Chu L . Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. JAMA. 1966; 195(6):445-52. View

Sprangers M, Lakhai W, Koudstaal W, Verhoeven M, Koel B, Vogels R . Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003; 41(11):5046-52. PMC: 262545. DOI: 10.1128/JCM.41.11.5046-5052.2003. View

Hoke Jr C, Hawksworth A, Snyder Jr C . Initial assessment of impact of adenovirus type 4 and type 7 vaccine on febrile respiratory illness and virus transmission in military basic trainees, March 2012. MSMR. 2012; 19(3):2-4. View

Houng H, Clavio S, Graham K, Kuschner R, Sun W, Russell K . Emergence of a new human adenovirus type 4 (Ad4) genotype: identification of a novel inverted terminal repeated (ITR) sequence from majority of Ad4 isolates from US military recruits. J Clin Virol. 2006; 35(4):381-7. DOI: 10.1016/j.jcv.2005.11.008. View

McNeill K, Ridgely Benton F, Monteith S, Tuchscherer M, Gaydos J . Epidemic spread of adenovirus type 4-associated acute respiratory disease between U.S. Army installations. Emerg Infect Dis. 2000; 6(4):415-9. PMC: 2640890. DOI: 10.3201/eid0604.000419. View

Purkayastha A, Su J, Carlisle S, Tibbetts C, Seto D . Genomic and bioinformatics analysis of HAdV-7, a human adenovirus of species B1 that causes acute respiratory disease: implications for vector development in human gene therapy. Virology. 2005; 332(1):114-29. DOI: 10.1016/j.virol.2004.10.041. View

Lyons A, Longfield J, Kuschner R, Straight T, Binn L, Seriwatana J . A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine. 2008; 26(23):2890-8. DOI: 10.1016/j.vaccine.2008.03.037. View

Top Jr F, DUDDING B, RUSSELL P, Buescher E . Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am J Epidemiol. 1971; 94(2):142-6. DOI: 10.1093/oxfordjournals.aje.a121306. View

Collins N, Beaty S, Wallace E, Li Y, Sanborn M, Yang Y . Differential Genome Replication of a Unique Single-Amino-Acid Mutation in the Adenovirus-4 Component of the Live Oral Adenovirus Type 4 and Type 7 Vaccine. Vaccines (Basel). 2023; 11(7). PMC: 10385111. DOI: 10.3390/vaccines11071144. View

10.

Collins N, Adhikari A, Yang Y, Kuschner R, Karasavvas N, Binn L . Live Oral Adenovirus Type 4 and Type 7 Vaccine Induces Durable Antibody Response. Vaccines (Basel). 2020; 8(3). PMC: 7564809. DOI: 10.3390/vaccines8030411. View

11.

Hoke Jr C, Snyder Jr C . History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system. Vaccine. 2013; 31(12):1623-32. DOI: 10.1016/j.vaccine.2012.12.029. View

12.

Kolavic-Gray S, Binn L, Sanchez J, Cersovsky S, Polyak C, Mitchell-Raymundo F . Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies. Clin Infect Dis. 2002; 35(7):808-18. DOI: 10.1086/342573. View

13.

Choudhry A, Mathena J, Albano J, Yacovone M, Collins L . Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits. Vaccine. 2016; 34(38):4558-4564. DOI: 10.1016/j.vaccine.2016.07.033. View

14.

Gray G, Goswami P, Malasig M, Hawksworth A, Trump D, Ryan M . Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics. For the Adenovirus Surveillance Group. Clin Infect Dis. 2000; 31(3):663-70. DOI: 10.1086/313999. View

15.

Top Jr F, Grossman R, Bartelloni P, Segal H, DUDDING B, RUSSELL P . Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis. 1971; 124(2):148-54. DOI: 10.1093/infdis/124.2.148. View

16.

Kuschner R, Russell K, Abuja M, Bauer K, Faix D, Hait H . A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits. Vaccine. 2013; 31(28):2963-71. DOI: 10.1016/j.vaccine.2013.04.035. View